OrbiMed-backed biotech quickly changes CEOs; Adaptimmune co-founder to lead Evaxion

→ Megan McGill has replaced David Lucchino as CEO of Brenig Therapeutics, an OrbiMed-backed neuro biotech that collected a $65 million Series A last summer. Lucchino was hired ...